Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xenon as antidepressant in treatment-resistant major depressive disorder
2006-005531-17Phase 2Active
- Sponsor
- Klinik für Anästhesiologie, Uniklinikum RWTH Aachen
- Start
- Aug 2007
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of xenon in major depressive disorder (MDD), sponsored by Klinik für Anästhesiologie, Uniklinikum RWTH Aachen. Primary endpoints: Change in Hamilton Depression Rating Scale (HDRS), Change in Beck Depression Inventory (BDI) and 2 more. Started Aug 2007; status: active.
02
Drugs
xenon
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2006-005531-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005531-17.